Elena Ferri , Cristian Caprari , Maria Angela Vandelli , Loretta L. Del Mercato , Cinzia Citti , Giuseppe Cannazza
{"title":"非靶向代谢物表征在微粒体分析使用液相色谱耦合高分辨率质谱:应用于卡异丙醇","authors":"Elena Ferri , Cristian Caprari , Maria Angela Vandelli , Loretta L. Del Mercato , Cinzia Citti , Giuseppe Cannazza","doi":"10.1016/j.jpba.2025.117091","DOIUrl":null,"url":null,"abstract":"<div><div>Understanding the metabolic fate of pharmaceutical compounds is critical for assessing drug safety and efficacy. A combination of advanced analytical techniques and <em>in vitro</em> models allows for detailed investigation of biotransformation processes. This study presents an integrated workflow using carisoprodol as a case study to demonstrate the application of modern analytical strategies for metabolic profiling. An analytical platform based on liquid chromatography–high-resolution mass spectrometry (LC-HRMS) was employed, operating in both MS¹ and MS² modes to investigate fragmentation behaviour and identify metabolites. Chromatographic separation was performed using a core-shell C<sub>18</sub> column under gradient elution. <em>In vitro</em> metabolic stability studies were conducted using rat liver microsomes, and a deuterated analogue was also tested to assist in structural elucidation of hydroxylated metabolites. Additionally, <em>in silico</em> metabolite prediction tools were applied and compared with experimental results. The compound showed slow metabolic degradation (<em>t₁/₂</em> = 233.72 ± 3.09 min) and low intrinsic clearance (<em>CL</em><sub><em>int, in vitro</em></sub> = 5.930 ± 0.078 µL/min/mg). LC-HRMS enabled identification of meprobamate and a hydroxylated derivative as major metabolites. MS/MS analysis of the deuterated metabolite excluded hydroxylation on the <em>n</em>-pentyl chain as reported in the literature, indicating alternative modification sites. <em>In silico</em> predictions correctly identified meprobamate but misassigned hydroxylation positions for the other metabolite. This study highlights the effectiveness of a multi-technique analytical approach for elucidating drug metabolism. The integration of LC-HRMS, isotopic labelling, and computational tools provides a comprehensive platform for metabolic characterization, while emphasizing the necessity of experimental validation in refining <em>in silico</em> predictions.</div></div>","PeriodicalId":16685,"journal":{"name":"Journal of pharmaceutical and biomedical analysis","volume":"266 ","pages":"Article 117091"},"PeriodicalIF":3.1000,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Non-targeted metabolite characterization in microsomal assay using liquid chromatography coupled to high-resolution mass spectrometry: Application to carisoprodol\",\"authors\":\"Elena Ferri , Cristian Caprari , Maria Angela Vandelli , Loretta L. Del Mercato , Cinzia Citti , Giuseppe Cannazza\",\"doi\":\"10.1016/j.jpba.2025.117091\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Understanding the metabolic fate of pharmaceutical compounds is critical for assessing drug safety and efficacy. A combination of advanced analytical techniques and <em>in vitro</em> models allows for detailed investigation of biotransformation processes. This study presents an integrated workflow using carisoprodol as a case study to demonstrate the application of modern analytical strategies for metabolic profiling. An analytical platform based on liquid chromatography–high-resolution mass spectrometry (LC-HRMS) was employed, operating in both MS¹ and MS² modes to investigate fragmentation behaviour and identify metabolites. Chromatographic separation was performed using a core-shell C<sub>18</sub> column under gradient elution. <em>In vitro</em> metabolic stability studies were conducted using rat liver microsomes, and a deuterated analogue was also tested to assist in structural elucidation of hydroxylated metabolites. Additionally, <em>in silico</em> metabolite prediction tools were applied and compared with experimental results. The compound showed slow metabolic degradation (<em>t₁/₂</em> = 233.72 ± 3.09 min) and low intrinsic clearance (<em>CL</em><sub><em>int, in vitro</em></sub> = 5.930 ± 0.078 µL/min/mg). LC-HRMS enabled identification of meprobamate and a hydroxylated derivative as major metabolites. MS/MS analysis of the deuterated metabolite excluded hydroxylation on the <em>n</em>-pentyl chain as reported in the literature, indicating alternative modification sites. <em>In silico</em> predictions correctly identified meprobamate but misassigned hydroxylation positions for the other metabolite. This study highlights the effectiveness of a multi-technique analytical approach for elucidating drug metabolism. The integration of LC-HRMS, isotopic labelling, and computational tools provides a comprehensive platform for metabolic characterization, while emphasizing the necessity of experimental validation in refining <em>in silico</em> predictions.</div></div>\",\"PeriodicalId\":16685,\"journal\":{\"name\":\"Journal of pharmaceutical and biomedical analysis\",\"volume\":\"266 \",\"pages\":\"Article 117091\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-08-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of pharmaceutical and biomedical analysis\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0731708525004327\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, ANALYTICAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of pharmaceutical and biomedical analysis","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0731708525004327","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, ANALYTICAL","Score":null,"Total":0}
Non-targeted metabolite characterization in microsomal assay using liquid chromatography coupled to high-resolution mass spectrometry: Application to carisoprodol
Understanding the metabolic fate of pharmaceutical compounds is critical for assessing drug safety and efficacy. A combination of advanced analytical techniques and in vitro models allows for detailed investigation of biotransformation processes. This study presents an integrated workflow using carisoprodol as a case study to demonstrate the application of modern analytical strategies for metabolic profiling. An analytical platform based on liquid chromatography–high-resolution mass spectrometry (LC-HRMS) was employed, operating in both MS¹ and MS² modes to investigate fragmentation behaviour and identify metabolites. Chromatographic separation was performed using a core-shell C18 column under gradient elution. In vitro metabolic stability studies were conducted using rat liver microsomes, and a deuterated analogue was also tested to assist in structural elucidation of hydroxylated metabolites. Additionally, in silico metabolite prediction tools were applied and compared with experimental results. The compound showed slow metabolic degradation (t₁/₂ = 233.72 ± 3.09 min) and low intrinsic clearance (CLint, in vitro = 5.930 ± 0.078 µL/min/mg). LC-HRMS enabled identification of meprobamate and a hydroxylated derivative as major metabolites. MS/MS analysis of the deuterated metabolite excluded hydroxylation on the n-pentyl chain as reported in the literature, indicating alternative modification sites. In silico predictions correctly identified meprobamate but misassigned hydroxylation positions for the other metabolite. This study highlights the effectiveness of a multi-technique analytical approach for elucidating drug metabolism. The integration of LC-HRMS, isotopic labelling, and computational tools provides a comprehensive platform for metabolic characterization, while emphasizing the necessity of experimental validation in refining in silico predictions.
期刊介绍:
This journal is an international medium directed towards the needs of academic, clinical, government and industrial analysis by publishing original research reports and critical reviews on pharmaceutical and biomedical analysis. It covers the interdisciplinary aspects of analysis in the pharmaceutical, biomedical and clinical sciences, including developments in analytical methodology, instrumentation, computation and interpretation. Submissions on novel applications focusing on drug purity and stability studies, pharmacokinetics, therapeutic monitoring, metabolic profiling; drug-related aspects of analytical biochemistry and forensic toxicology; quality assurance in the pharmaceutical industry are also welcome.
Studies from areas of well established and poorly selective methods, such as UV-VIS spectrophotometry (including derivative and multi-wavelength measurements), basic electroanalytical (potentiometric, polarographic and voltammetric) methods, fluorimetry, flow-injection analysis, etc. are accepted for publication in exceptional cases only, if a unique and substantial advantage over presently known systems is demonstrated. The same applies to the assay of simple drug formulations by any kind of methods and the determination of drugs in biological samples based merely on spiked samples. Drug purity/stability studies should contain information on the structure elucidation of the impurities/degradants.